Articles

B.C. researchers, advocates, and companies at forefront of Canada's psychedelic revolution

B.C. researchers, advocates, and companies at forefront of Canada's psychedelic revolution

The Georgia Straight's Charlie Smith explores the history of psychedelic-assisted psychotherapy in British Columbia and the role that Vancouver companies like Numinus are playing in its revival.…

Is psilocybin the next cannabis? New research is chipping away at the stigma attached to psychedelics

Is psilocybin the next cannabis? New research is chipping away at the stigma attached to psychedelics

The Toronto Star explores the difference between microdosing and psychedelic-assisted psychotherapy, the research driving renewed interest in the field, and how regulation of these substances could…

MAPS Canada advances understanding about psychedelic medicines

MAPS Canada advances understanding about psychedelic medicines

For the past decade, executive director Mark Haden has been educating physicians on how psychedelic substances could help patients with posttraumatic stress disorder, treatment-resistant depression,…

Company with Nanaimo lab gets federal approval for psychedelic drug research

Company with Nanaimo lab gets federal approval for psychedelic drug research

Numinus's recently amended Health Canada licence allows the company to produce and extract psilocybin from mushrooms. The Nanaimo News Bulletin speaks with Numinus CEO Payton Nyquvest about the…

Conversations That Matter: Payton Nyquvest and Dr. Evan Wood

Conversations That Matter: Payton Nyquvest and Dr. Evan Wood

In a special to the Vancouver Sun, Simon Fraser University's Stu McNish speaks with Numinus CEO Payton Nyquvest and Chief Medical Officer Dr. Evan Wood. Click here to read more.

Healthcare company Numinus looks to address mental health and addiction with psychedelic assisted therapy

Healthcare company Numinus looks to address mental health and addiction with psychedelic assisted therapy

Numinus leaders explore how research, development, testing, and treatment centres will be key to advancing and implementing psychedelic-assisted therapies. Click here to read more.

Healthcare company Numinus believes psychedelic assisted therapy can improve mental health outcomes

Healthcare company Numinus believes psychedelic assisted therapy can improve mental health outcomes

Numinus CEO Payton Nyquvest and Chief Medical Officer Dr. Evan Wood discuss the potential of psychedelic-assisted psychotherapy to transform existing treatment models of mental health and addition -…

The business of producing psychedelics for science

The business of producing psychedelics for science

The Daily Hive's Peter Smith speaks to Numinus CEO Payton Nyquvest about the business side of psychedelic-assisted therapy research and how Numinus's amended Health Canada licence puts them in a…

Medical Psilocybin and the Emerging “Functional” Mushrooms Market

Medical Psilocybin and the Emerging “Functional” Mushrooms Market

Investing News Network highlights the investment opportunity in the psychedelic-assisted therapy space and considers Numinus's unique position. Click here to read the full article.

Numinus licensed by Health Canada to extract and research psilocybin

Numinus licensed by Health Canada to extract and research psilocybin

Numinus CEO Payton Nyquvest and Chief Operating Officer Michael Tan spoke to Mugglehead about an amendment to the company's Health Canada licence which will allow them to produce and extract…

Numinus Licencing Amendment: We Speak to the Team

Numinus Licencing Amendment: We Speak to the Team

Numinus Chief Operating Officer Michael Tan explains what the company's recent Health Canada licence amendment, which will allow them to produce and extract psilocybin from mushrooms, means for…

Psychedelics Stocks to Watch

Psychedelics Stocks to Watch

Investing News Network highlights Numinus' unique value proposition in this article. Click here to read the full article.